BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 26026994)

  • 1. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.
    Stevens PL; Lenihan DJ
    Curr Cardiol Rep; 2015 Jul; 17(7):603. PubMed ID: 26026994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Cohen V; Gosavi S; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Am J Cardiol; 2011 May; 107(9):1375-80. PubMed ID: 21371685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
    Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
    Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.
    Lenihan DJ; Stevens PL; Massey M; Plana JC; Araujo DM; Fanale MA; Fayad LE; Fisch MJ; Yeh ET
    J Card Fail; 2016 Jun; 22(6):433-8. PubMed ID: 27079675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
    Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
    Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
    J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
    Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
    J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
    Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.
    Cardinale D; Ciceri F; Latini R; Franzosi MG; Sandri MT; Civelli M; Cucchi G; Menatti E; Mangiavacchi M; Cavina R; Barbieri E; Gori S; Colombo A; Curigliano G; Salvatici M; Rizzo A; Ghisoni F; Bianchi A; Falci C; Aquilina M; Rocca A; Monopoli A; Milandri C; Rossetti G; Bregni M; Sicuro M; Malossi A; Nassiacos D; Verusio C; Giordano M; Staszewsky L; Barlera S; Nicolis EB; Magnoli M; Masson S; Cipolla CM;
    Eur J Cancer; 2018 May; 94():126-137. PubMed ID: 29567630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques.
    Di Lisi D; Manno G; Novo G
    Curr Probl Cardiol; 2021 Jun; 46(6):100818. PubMed ID: 33756178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
    Christenson ES; James T; Agrawal V; Park BH
    Clin Biochem; 2015 Mar; 48(4-5):223-35. PubMed ID: 25445234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
    Saganelidze K; Kavtaradze N
    Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
    Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies.
    Witteles RM
    J Card Fail; 2016 Jun; 22(6):459-64. PubMed ID: 27038641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
    Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
    Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study.
    Bergamini C; Torelli F; Ghiselli L; Rossi A; Trevisani L; Vinco G; Truong S; Benfari G; LA Russa F; Golia G; Molino A; Vassanelli C
    Minerva Cardioangiol; 2017 Jun; 65(3):278-287. PubMed ID: 27886160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
    Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
    ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
    Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P
    JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Possibilities of Early Detection of Cardiotoxicity of Cytostatic Treatment.
    Balážová K; Kubincová D
    Klin Onkol; 2020; 33(3):208-213. PubMed ID: 32683877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for early detection of cardiotoxicities from anticancer therapy in adults: evolving imaging techniques and emerging serum biomarkers.
    Akhter N; Murtagh G; Yancy C
    Future Oncol; 2015; 11(14):2093-103. PubMed ID: 26198839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.